Golden has been acquired by ComplyAdvantage.Read about it here ⟶

‌

US Patent 10624880 Predicting response to alvocidib by mitochondrial profiling

Patent 10624880 was granted and assigned to Tolero Pharmaceuticals on April, 2020 by the United States Patent and Trademark Office.

Overview Structured Data Issues Contributors Activity

Is a

0

Patent attributes

Patent Applicant

Tolero Pharmaceuticals

0

Current Assignee

Tolero Pharmaceuticals

0

Patent Jurisdiction

United States Patent and Trademark Office

0

Patent Number

Date of Patent

April 21, 2020

0

Patent Application Number

164258260

Date Filed

May 29, 2019

0

Patent Citations

US Patent 10259835 Alvocidib prodrugs having increased bioavailability

US Patent 10357488 Predicting response to alvocidib by mitochondrial profiling

0

US Patent 10422788 Profiling peptides and methods for sensitivity profiling

US Patent 10132797 Profiling peptides and methods for sensitivity profiling

US Patent 10267787 Profiling peptides and methods for sensitivity profiling

0

Patent Citations Received

US Patent 12077554 CDK9 inhibitors and polymorphs thereof for use as agents for treatment of cancer

0

US Patent 11530231 CDK9 inhibitors and polymorphs thereof for use as agents for treatment of cancer

0

US Patent 11034710 CDK9 inhibitors and polymorphs thereof for use as agents for treatment of cancer

US Patent 11279694 Alvocidib prodrugs and their use as protein kinase inhibitors

US Patent 11497756 Treatment regimen for cancers that are insensitive to BCL-2 inhibitors using the MCL-1 inhibitor alvocidib

Patent Primary Examiner

0

No article content yet.

Timeline

No Timeline data yet.

Further Resources

Title

Author

Link

Type

Date

No Further Resources data yet.

References

Find more entities like US Patent 10624880 Predicting response to alvocidib by mitochondrial profiling

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.

Open Query Tool

Golden Query Tool